UK markets closed

Inhibikase Therapeutics, Inc. (IKT)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
1.5950+0.0250 (+1.59%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 11.51M
Enterprise value 1.97M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.70
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.34

Trading information

Stock price history

Beta (5Y monthly) 1.33
52-week change 3-36.71%
S&P500 52-week change 318.96%
52-week high 33.8200
52-week low 30.7900
50-day moving average 31.5605
200-day moving average 31.6444

Share statistics

Avg vol (3-month) 342.75k
Avg vol (10-day) 328.45k
Shares outstanding 57.22M
Implied shares outstanding 67.4M
Float 85.14M
% held by insiders 112.43%
% held by institutions 114.38%
Shares short (15 Jul 2024) 445.8k
Short ratio (15 Jul 2024) 41.61
Short % of float (15 Jul 2024) 40.72%
Short % of shares outstanding (15 Jul 2024) 40.63%
Shares short (prior month 14 Jun 2024) 493.49k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:6
Last split date 330 Jun 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-10,285.34%

Management effectiveness

Return on assets (ttm)-64.23%
Return on equity (ttm)-119.64%

Income statement

Revenue (ttm)195.98k
Revenue per share (ttm)0.03
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -19.98M
Net income avi to common (ttm)-19.2M
Diluted EPS (ttm)-3.3200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)9.75M
Total cash per share (mrq)1.5
Total debt (mrq)490.1k
Total debt/equity (mrq)7.23%
Current ratio (mrq)2.55
Book value per share (mrq)1.05

Cash flow statement

Operating cash flow (ttm)-15.98M
Levered free cash flow (ttm)-9.87M